Immorta Bio completes preclinical studies of AI designed senolytic peptide
Immorta Bio completed its planned preclinical studies of SenoMune-0257 and plans initial human testing before the end of 2026, the company said in a press release.
SenoMune-0257 is a synthetic nine amino acid peptide designed with AI to stimulate immune responses against senescent cells. Immorta Bio said laboratory studies showed that the candidate stimulated cytotoxic T cells that selectively eliminated senescent cells while sparing healthy cells under the tested conditions.
The company identified dozens of peptide candidates through computational analysis before selecting SenoMune-0257 for laboratory testing. The therapy remains investigational, and its safety and effectiveness have not been established in humans.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 12 Flo Health Partners With Google Health on Wearables and Women's Health AI Oct 12 POMDOCTOR Outlines Predictive Healthcare Strategy Oct 12 Lunit and Discovery Life Sciences Partner on AI Tissue Analysis Oct 12 Emplify Health adds Pearl Health AI tools for Medicare care Oct 12 Sopris Capital Acquires Blackford Analysis from BayerLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
MediSights Reports Study Using AI Agents for Myeloma Market Research
Immunomatics Receives $100,000 Investment From GenDx Cofounder
Insilico Medicine Selects AI Designed Obesity Drug Candidate ISM1354
NAVER D2SF Backs ImpriMed in $10 Million Bridge Round
ARPA-H Funds $28.6 Million AI Protein Research Project
Daily AI Brief: the AI news that matters, in your inbox.